» Articles » PMID: 35945394

Utility of Myxedema Score As a Predictor of Mortality in Myxedema Coma

Overview
Publisher Springer
Specialty Endocrinology
Date 2022 Aug 9
PMID 35945394
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Myxedema crisis (MC) is a rare condition. There is a dearth of data regarding the predictors of mortality in MC. Predictive scores for mortality specific to the clinical and biochemical profile of MC are still lacking.

Design And Methods: All consecutive patients presenting with MC from September 2006 to December 2020 comprised the new cohort. Patients managed between January 1999 and August 2006 comprised the old cohort. Both cohorts were compared for the determination of secular trends. Combined analysis of both the cohorts was done for clinico-demographic profile and predictors of mortality. Myxedema score (MS) and qSOFA (Quick Sequential Organ Failure Assessment) score were evaluated in all the patients.

Results: A total of forty-one patients (new cohort; n = 18 and old cohort; n = 23) were enrolled into the study. There was a female predominance (80.5%). Nearly half (51.2%) of the patients were newly diagnosed with hypothyroidism on admission. Overall mortality was 60.9%. On comparative analysis among survivors and non-survivors, female gender (OR 20.4, p value 0.018), need for mechanical ventilation (OR16.4, p value 0.009), in-hospital hypotension (OR 9.1, p value 0.020), and high qSOFA score (OR 7.1, p value 0.023) predicted mortality. MS of > 90 had significantly higher mortality (OR-11.8, p value - 0.026) while MS of > 110 had 100% mortality. There was no change in secular trends over last 20 years. There was no difference in outcome of patients receiving oral or IV levothyroxine.

Conclusion: Myxedema crisis is associated with high mortality despite improvement in health care services. The current study is first to elucidate the role of the MS in predicting mortality in patients with MC.

Citing Articles

Frequent Seronegative Primary Hypothyroidism in Myxedema Coma in Japan: Three Case Reports With a Systematic Review.

Okuno Y, Mukai K, Tamura Y, Hayakawa T, Fukuhara A, Shimomura I Case Rep Endocrinol. 2024; 2024:2524019.

PMID: 39435032 PMC: 11493479. DOI: 10.1155/2024/2524019.


The Development of Myxedema Coma in the Setting of Euthyroid Sick Syndrome: A Diagnostic Dilemma and Review of Management Strategies.

Holder S, Unbehaun G, Pyfrom D, Greaves A, Muhammad A, Hsu F Cureus. 2024; 16(7):e64406.

PMID: 39130985 PMC: 11317061. DOI: 10.7759/cureus.64406.


Acute parkinsonism in a patient with myxedema crisis: A case report.

Gupta R, Chaudhary S, Sood V, Chauhan N, Chauhan N, Kapoor D Med Int (Lond). 2024; 4(5):49.

PMID: 39006812 PMC: 11240856. DOI: 10.3892/mi.2024.173.


Increased incidence of myxedema coma during the COVID-19 pandemic and in the post pandemic era: a single-center case series.

Sokolowski G, Studen K, Opalinska M, Wegrzyn K, Motyka M, Gilis-Januszewska A Intern Emerg Med. 2024; 19(7):1921-1928.

PMID: 38967885 PMC: 11467063. DOI: 10.1007/s11739-024-03690-9.


Optic Neuropathy Following Acute Decompensated Hypothyroidism (Myxedema Crisis).

McBee D, Lee P, Zhou Y, AlRyalat S, Lee A Cureus. 2023; 15(10):e47793.

PMID: 38022260 PMC: 10679792. DOI: 10.7759/cureus.47793.